Ortho Clinical Diagnostics Holdings

Ortho Clinical Diagnostics is a global leader of in vitro diagnostics dedicated to improving and saving lives through innovative laboratory testing and blood-typing solutions. Because Every Test is a LifeTM, we never stop innovating to offer streamlined, sustainable laboratory solutions that deliver fast, accurate, reliable test results that support exceptional patient care. As a trusted partner of hospitals, hospital networks, blood banks, and labs around the world, we proudly serve the clinical laboratory and transfusion medicine communities with customized solutions that enhance clinical outcomes, improve lab performance, overcome staffing challenges and better manage costs.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Ortho-Clinical Diagnostics is a manufacturer of medical equipment. They provide hospitals, hospital networks, clinical laboratories, and blood banks. They specialize in in vitro diagnostics and are dedicated to improving them through laboratory testing and blood-typing solutions.

RARITAN, N.J., July 7, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play, in-vitro diagnostics (IVD) companies, today announced its distribution agreement with Thermo Fisher Scientific™ to provide and support MAS™ Quality Controls and LabLink xL™ Quality Assurance Software through Ortho's VITROS® QC Solutions to VITROS® System customers worldwide.

Ortho Clinical Diagnostics Announces Partnership With Thermo Fisher Scientific

RARITAN, N.J., June 7, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced its semi-automated ORTHO OPTIX™ Reader, which allows lower-volume transfusion labs to elevate their standard of patient care with the quality of results expected of an automated platform, is now available in the United States and Puerto Rico.

ORTHO OPTIX™ Reader Completes Transfusion Medicine Portfolio, Now Available in the United States and Puerto Rico

- Ortho is the only company that offers laboratories in the U.S. a quantitative test in combination with a nucleocapsid test - Both new antibody tests help health care teams differentiate the cause of antibodies against SARS-CoV-2 - Ortho's new VITROS® Anti-SARS-CoV-2 IgG Quantitative Antibody test targets the S1 spike protein and is calibrated to the WHO International Standard for anti-SARS-CoV-2 IgG antibodies, which gives clinicians and public health leaders a standard tool to measure antibody response to SARS-CoV-2 RARITAN, N.J., May 21, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced the launch of the first quantitative COVID-19 IgG antibody test in addition to a total COVID-19 nucleocapsid antibody test.

Ortho Clinical Diagnostics Simultaneously Launches First Quantitative COVID-19 IgG Spike Antibody Test As Well As A Nucleocapsid Antibody Test to Help Differentiate Cause of Antibody Response

RARITAN, N.J., May 20, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics (IVD) companies, today announced that members of its management team are scheduled to present in two upcoming investor conferences:

Ortho Clinical Diagnostics to Present at Upcoming Investor Conferences

Ortho Clinical Diagnostics Holdings plc (OCDX) CEO Chris Smith on Q1 2021 Results - Earnings Call Transcript

First Quarter Revenue Growth Exceeds Company's Expectations at 24.2%, Supporting Increase in 2021 Guidance First Quarter Revenue Growth Exceeds Company's Expectations at 24.2%, Supporting Increase in 2021 Guidance

Ortho Clinical Diagnostics Reports First Quarter 2021 Results

- Ortho's VITROS® Anti-SARS-CoV-2 IgG Quantitative Antibody test is traceable to the WHO International Standard for anti-SARS-CoV-2 IgG antibodies, which is developed to facilitate the standardization of SARS-CoV-2 serological methods - The test gives clinicians and public health leaders a standard tool to evaluate immune response after infection or vaccination RARITAN, N.J., May 5, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced its quantitative COVID-19 IgG antibody test achieved CE Mark.

Ortho Clinical Diagnostics Launches Quantitative COVID-19 IgG Antibody Test with CE Mark

ORTHO VISION is the leading choice for blood banks RARITAN, N.J., May 3, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced the availability of enhanced ORTHO VISION® Swift and ORTHO VISION® Max Swift Analyzers.

Global Transfusion Medicine Leader Ortho Clinical Diagnostics Launches Next Gen ORTHO VISION® Swift Platform

RARITAN, N.J., April 26, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (NASDAQ: OCDX), one of the world's largest pure-play in vitro diagnostics (IVD) companies, has been recognized with a prestigious silver 2021 Edison Award for its  VITROS® COVID-19 testing solutions, helping labs meet demands of the pandemic with reliable mass-scale testing options.

Ortho Clinical Diagnostics Recognized With Prestigious Edison Award for Highly Accurate COVID-19 Solutions Capable of Mass-Scale Testing

RARITAN, N.J., April 21, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced it will report results for its first quarter 2021 ended April 4, 2021, after the market close on May 5, 2021.

Ortho Clinical Diagnostics to Report First Quarter 2021 Results on May 5, 2021

RARITAN, N.J., April 13, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced it received CE Marking for its VITROS® SARS-CoV-2 Antigen Test, initially launched in October 2020.

Ortho's VITROS® SARS-CoV-2 Antigen Test for High-Volume COVID-19 Testing Receives CE Mark; Allows for More Convenient Sample Collection and Expanded Viral Transport Media

- The new contract will deliver Ortho with funding for capacity expansion to provide up to 6.7 million COVID-19 tests per month dedicated for the U.S. market over the next 12-14 months  RARITAN, N.J., March 31, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play IVD companies, today announced that through its continued partnership with the Biomedical Advanced Research and Development Authority (BARDA) and the U.S. Department of Defense, the company been awarded an undefinitized contract which will lead to a $53.7 million contract that will support a more than three-fold increase in domestic production capabilities for its COVID-19 serological and diagnostic testing solutions.

Ortho Announces Plans to Accelerate COVID-19 Antigen and Antibody Test Development Through New Contract with BARDA and the Department of Defense

RARITAN, N.J., March 23, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics companies, today announced it received authorization from the U.S. Food and Drug Administration to update key claims for the VITROS® SARS-CoV-2 Antigen Test, the first high-volume SARS-CoV-2 antigen assay to receive Emergency Use Authorization (EUA) in the United States.

Ortho's VITROS® SARS-CoV-2 Antigen Test for High-Volume Testing Receives FDA Emergency Use Authorization for New Performance, Sensitivity Data

Fourth Quarter Revenue Growth Ahead of Company Expectations at 9.1% Fourth Quarter Revenue Growth Ahead of Company Expectations at 9.1%

REPLACING: Ortho Clinical Diagnostics Reports Fourth Quarter and Fiscal Year 2020 Results

Ortho Clinical Diagnostics Reports Fourth Quarter and Fiscal Year 2020 Results

Bolt Biotherapeutics

908 Devices

Midwest Holding

NexImmune

Last year was a monster year for the initial public offering market, and 2021 looks like it could provide a repeat performance.

5 Recent Red-Hot IPOs Are Being Added to the Russell 2000 Next Week

RARITAN, N.J., March 8, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics (Nasdaq: OCDX), one of the world's largest pure-play IVD companies dedicated to transforming patient care, today announced that its new VITROS® Anti-SARS-CoV-2 Total 2 Antibody assay and VITROS® Anti-SARS-CoV-2 IgG 2...

Ortho's New COVID-19 Total and IgG Antibody Tests Receive CE Mark for Semi-Quantitative Results

RARITAN, N.J., March 04, 2021 (GLOBE NEWSWIRE) -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX), one of the world's largest pure-play in vitro diagnostics (IVD) companies dedicated to transforming patient care, today announced it will report results for the fourth quarter and full year 2020 ended January 3, 2021, after the market close on March 18, 2021.

Ortho Clinical Diagnostics to Report Fourth Quarter and Full Year 2020 Results on March 18, 2021

Former CEO of Charles Schwab Investment Management will also serve as audit committee chair Former CEO of Charles Schwab Investment Management will also serve as audit committee chair

Ortho Clinical Diagnostics Names Evelyn Dilsaver to Board of Directors

Agencies Provide Stable Outlook Following Company's Initial Public Offering Agencies Provide Stable Outlook Following Company's Initial Public Offering

Ortho Clinical Diagnostics Announces Rating Upgrades by S&P Global and Moody's

Increases facility by $150 million and extends it to 2026

Ortho Clinical Diagnostics Amends Credit Agreement to Extend Maturity and Increase Borrowing Capacity Under its Revolving Credit Facility

RARITAN, N.J., Feb. 4, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics Holdings plc (Nasdaq: OCDX) ("Ortho"), the world's largest pure-play in vitro diagnostics company dedicated to improving and saving lives through innovative laboratory testing and blood-typing solutions, today...

Ortho Clinical Diagnostics Announces Closing of Full Over-Allotment Option from Initial Public Offering

After its shares fell nearly 7% in a public debut last week, Ortho Clinical Diagnostics Holdings PLC (NASDAQ:OCDX) is clawing its way back to a modicum of respectability. The Raritan, New Jersey-based company is now trading at about $18 after hitting the public market at an already reduced price of $17.

Ortho Clinical's Public Debut Proves Disappointing

RARITAN, N.J., Jan. 27, 2021 /PRNewswire/ -- Ortho Clinical Diagnostics Holdings plc ("Ortho"), the world's largest pure-play in vitro diagnostics company dedicated to improving and saving lives through innovative laboratory testing and blood-typing solutions, today announced the pricing...

News for Ortho Clinical Diagnostics Holdings Stock (OCDX)